About MB-109 (MB-101 (IL13Ra2 targeted CAR-T cells) + MB-108 oncolytic virus) MB-109 is Mustang's designation for the treatment regimen combining MB-101 (IL13Ra2-targeted CAR-T cell therapy ...
1City of Hope Beckman Research Institute and National Medical, Duarte, CA.
IL13RA2 is being clinically tested as a possible cancer vaccination and CAR-T treatment target as a glioma-specific cell-surface epitope. Functionally, there are two categories of IL-13 receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback